Upgrade to SI Premium - Free Trial

H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX)

June 8, 2026 6:55 AM
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $34.00 price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments